

# PEDONCOVID - SFCE national cohort on SARS-CoV-2 (COVID-19) infections in paediatric oncology-haematology

Responsable(s) :ROUGER-GAUDICHON Jérémie

Date de modification : 05/05/2021 | Version : 1 | ID : 73865

## Général

### Identification

Nom détaillé SFCE national cohort on SARS-CoV-2 (COVID-19) infections in paediatric oncology-haematology

Sigle ou acronyme PEDONCOVID

### Thématiques générales

Domaine médical Pediatrics

Etude en lien avec la Covid-19 Yes

Pathologie, précisions Paediatric oncology

Mots-clés cancer; paediatrics; chemotherapy; SARS-CoV-2; COVID-19

### Responsable(s) scientifique(s)

Nom du responsable ROUGER-GAUDICHON

Prénom Jérémie

Organisme CHU Caen Normandie

### Collaborations

### Financements

### Gouvernance de la base de données

Organisation(s) responsable(s) ou promoteur CHU Caen Normandie

Statut de l'organisation Secteur Public

### Contact(s) supplémentaire(s)

## Caractéristiques

### Type de base de données

Type de base de données

Study databases

Base de données issues d'enquêtes, précisions

Cohort study

Origine du recrutement des participants

A selection of health institutions and services

Le recrutement dans la base de données s'effectue dans le cadre d'une étude interventionnelle

No

## Objectif de la base de données

Objectif principal

Describe the presentation and clinical course of SARS-CoV-2 infection among patients followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre, for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy.

Critères d'inclusion

Children and legal representatives, or adult patients having received information on the study  
AND  
- Patient followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy, with a cancer treatment either ongoing or completed within the past 6 months, or a history of allogeneic haematopoietic stem cell transplantation with immunosuppressant therapy ongoing or discontinued within the past 6 months, or a history of CAR-T cell therapy  
AND  
- Diagnosis of SARS-CoV-2 infection confirmed by PCR or positive IgM serology  
OR  
- Clinical and radiological diagnosis characteristic of SARS-CoV-2 infection without confirmation of infection by PCR or positive IgM serology with:  
o Presence of at least 2 of the following signs in the event of contact with a subject currently presenting SARS-CoV-2 positive infection, or 3 of the following signs in the absence of contact: fever, cough, dysgeusia, dysosmia, myalgia, chest pain, dyspnoea, signs of respiratory distress, rhinorrhoea or nasopharyngeal congestion, diarrhoea, headaches, recent onset or exacerbation of asthenia and rash.  
AND

o One or more radiological abnormalities observed on chest CT scan compatible with a diagnosis of COVID-19: peripheral and/or subpleural and/or bilateral ground-glass opacities, intralobular thickening with a “crazy-paving” appearance, linear condensations with or without peripheral halo (reverse halo sign).

## Type de population

Age  
Newborns (birth to 28 days)  
Infant (28 days to 2 years)  
Early childhood (2 to 5 years)  
Childhood (6 to 13 years)  
Adolescence (13 to 18 years)

Population concernée Sick population

Pathologie II - Neoplasms

Sexe  
Male  
Woman

Champ géographique National

## Collecte

Dates

Taille de la base de données

Taille de la base de données (en nombre d'individus) < 500 individuals

## Données

Activité de la base Current data collection

Type de données recueillies  
Clinical data  
Biological data

Données cliniques, précisions Direct physical measures

Existence d'une bibliothèque No

## Modalités

Pathologie suivies

## Valorisation et accès

Valorisation et accès

